Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Moffitt, Vermillion Collaborate to Model Improvements in Ovarian Cancer Care

Published: Monday, May 12, 2014
Last Updated: Monday, May 12, 2014
Bookmark and Share
The purpose of the study is to produce clinical and economic data to support a new value-based practice model.

The study will be led by Johnathan M. Lancaster, M.D., Ph.D., a gynecologic oncologist, expert in personalized medicine and president of the Moffitt Medical Group, and funded through an unrestricted grant fromAustin-based Vermillion, Inc. It will feature two phases, the first phase will be retrospective, and will benchmark the care standards and variances provided to patients with ovarian, fallopian tube and/or primary peritoneal cancer. The second phase will model improvements in care quality and cost that may be afforded by creating a standardized triage algorithm employing different FDA-cleared or prototype multi-marker blood tests, along with established clinical diagnostic or prognostic factors such as pelvic exams and ultrasound imaging.

"It is imperative that we rapidly develop high-quality, cost-effective strategies for the diagnosis and treatment of ovarian cancer," said Dr. Lancaster. "Multiple studies have shown that patients with ovarian cancer who are treated from the beginning by a board-certified gynecologic oncologist have a better chance of beating the disease. Yet in the U.S., fewer than half of the patients with the disease receive care from a gynecologic oncologist. This likely contributes to the high death rate from the disease, and is simply unfair to patients.  We have a duty to develop clinical management strategies that will change this pattern – to improve survival rates, quality of life, and the cost-effectiveness of care in our communities."

Nearly 22,000 women are diagnosed with ovarian cancer in the U.S. annually, and more than 14,000 die each year, making it the deadliest of all gynecologic cancers. Treatment advances during the last three decades have modestly improved the average length of survival following a diagnosis of ovarian cancer. Women diagnosed with ovarian cancer in 1975 had a five-year survival rate of 33.6 percent. Today, the rate is still only 44 percent.

"Today, on World Ovarian Cancer Day, we honor the thousands of women who have lost their lives to ovarian cancer, as well as the women, their families and care teams who are fighting this disease," said James LaFrance, chairman, president and chief executive officer of Vermillion. "Reducing the burden of ovarian cancer is central to our mission and to the health of women in the U.S. With the expertise of Dr. Lancaster and the Moffitt team, we believe this effort will facilitate an important dialogue and establish a path to improving ovarian cancer care and outcomes."

The study will measure the baseline triage effectiveness, treatment standards, early outcomes and cost of care for patients diagnosed with an adnexal malignancy. From this baseline, potential improvement in care and cost effectiveness will be calculated for different triage protocols, including molecular or proteomic biomarkers, such as the OVA1® blood test. OVA1 is an FDA-cleared, highly sensitive blood test that offers a way to predict whether a suspicious pelvic mass is malignant or benign, helping triage a woman to a gynecologic oncologist more quickly. OVA1 measures the levels of five tumor-secreted proteins (Beta-2 microglobulin, CA 125II, apolipoprotein A1, prealbumin and transferrin), while measuring the host response to ovarian cancer. Studies have shown that OVA1 improves the pre-surgical detection of ovarian cancer, regardless of stage or subtype, in patients with planned surgery for a suspicious mass.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Wednesday, June 22, 2016
Protein Complex Linked to Cancer Growth May Also Help Fight Tumors
Researchers have discovered a gene expression signature that may lead to new immune therapies for lung cancer patients.
Thursday, July 25, 2013
Moffitt Cancer Center Researchers Identify Genetic Variants for Prostate Cancers
Researchers have developed a method for identifying aggressive prostate cancers that require immediate therapy.
Monday, June 24, 2013
Race, Ethnicity Affect Likelihood of Finding a Suitable Unrelated Stem Cell Donor
Researchers at Moffitt Cancer Center describe the greater difficulty in finding matched, unrelated donors for non-Caucasian patients who are candidates for hematopoietic cell transplantation (HCT).
Monday, September 17, 2012
Scientific News
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
New Nanoparticle Technology Developed to Treat Aggressive Thyroid Cancer
Researchers from Brigham and Women’s Hospital have developed a nanoplatform that can deliver RNAi agents to sites of anaplastic thyroid cancer.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!